| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/06/2006 | US7056492 Mycoplasma hyopneumoniae vaccine and methods for reducing Mycoplasma bovis pneumonia in cattle |
| 06/06/2006 | CA2363493C Attenuated forms of bovine viral diarrhea virus |
| 06/06/2006 | CA2120153C Recombinant immunotoxins |
| 06/06/2006 | CA2116980C Chimeric and/or growth-restricted flaviviruses |
| 06/06/2006 | CA2071214C Method of delivering molecules into eukaryotic cells |
| 06/06/2006 | CA1341506C Factor viii coagulant polypeptides and monoclonal antibodies to them |
| 06/01/2006 | WO2006058300A2 Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (pth) 1-84 |
| 06/01/2006 | WO2006058043A2 Contraceptive vaccines for dogs and cats based on egg membrane antigens |
| 06/01/2006 | WO2006057951A2 Methods and compositions for the treatment of graft failure |
| 06/01/2006 | WO2006057623A1 Runx3 antibodies and method of obtaining the antibodies |
| 06/01/2006 | WO2006057454A1 A method of prime-boost vaccination |
| 06/01/2006 | WO2006057027A1 Antigenic epitopes of interleukin-21, related antibodies and their use in medical field |
| 06/01/2006 | WO2006056853A1 Methods for cultivating lawsonia intracellularis |
| 06/01/2006 | WO2006056841A1 Multiple-strain mycoplasma hyopneumoniae vaccines |
| 06/01/2006 | WO2006056823A1 Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1 |
| 06/01/2006 | WO2006056769A1 Methods of studying tolerance in mhc-ii transgenic animals |
| 06/01/2006 | WO2006056306A2 Hydrogel polymeric conjugates of a prodrug |
| 06/01/2006 | WO2006056245A1 Use of a human chitinase-like protein in diagnosis and therapy |
| 06/01/2006 | WO2006056142A1 Cpg single-strand deoxynucleotides for use as adjuvant |
| 06/01/2006 | WO2006056054A1 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| 06/01/2006 | WO2006056031A1 Use of ferrous ions for increasing the immunoreactivity of immunoglobulin preparations |
| 06/01/2006 | WO2006056006A1 Equine west nile virus immunotherapy |
| 06/01/2006 | WO2006029020A3 Treatments of refractory cancers using na+/k+-atpase inhibitors |
| 06/01/2006 | WO2006024240A3 Vaccine composition against hepatitis c virus |
| 06/01/2006 | WO2006012092A3 Safer attenuated virus vaccines with missing or diminished latency of infection |
| 06/01/2006 | WO2006010106A3 Dna-based vaccination of retroviral-infected individuals undergoing treatment |
| 06/01/2006 | WO2006005825A3 Novel polypeptides for isolating in vitro and preventing staphyloccocal infections on joint prostheses and other implanted foreign materials |
| 06/01/2006 | WO2005117976A3 Method of increasing radiation sensitivity by inhibition of beta one integrin |
| 06/01/2006 | WO2005117975A3 Methods for treating vascular disease |
| 06/01/2006 | WO2005115458A9 Methods and compositions related to regulation of nucleo-cytoplasmic localization of e1 dna helicase in papillomaviruses |
| 06/01/2006 | WO2005103243A3 Carboxypeptidases b from anopheles gambiae. compositions comprising them, vaccine applications and use as therapeutical targets |
| 06/01/2006 | WO2005097188A3 Method to decrease the risk of a vaccine-induced chronic immune mediated disorder in humans with a family history of the disorder |
| 06/01/2006 | WO2005058941A3 Aβ IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME |
| 06/01/2006 | WO2005049642A3 Genome of legionella pneumophila paris and lens strain-diagnostic and epidemiological applications |
| 06/01/2006 | WO2005047478A3 Compositions and methods for regulation of tumor necrosis factor-alpha |
| 06/01/2006 | WO2005001025A3 Immunoglobulin chimeric monomer-dimer hybrids |
| 06/01/2006 | WO2004091550A3 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives |
| 06/01/2006 | WO2004066932A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 06/01/2006 | WO2003090675A3 Methods and compositions useful for treating prostate cancer |
| 06/01/2006 | US20060116325 Methods and compositions for inhibiting hiv-coreceptor interactions |
| 06/01/2006 | US20060115897 Compositions and methods modulating variola and vaccinia virus |
| 06/01/2006 | US20060115827 Genetic markers for predicting disease and treatment outcome |
| 06/01/2006 | US20060115499 Liquid allergy vaccine formulation for oromucosal administration |
| 06/01/2006 | US20060115498 DNA encoding an antigenic protein of Eimeria apical membrane antigen 1 and use thereof |
| 06/01/2006 | US20060115497 Mycobacterium strains with modified erp gene and vaccine composition containing same |
| 06/01/2006 | US20060115496 Toxoplasma gondii proteins, nucleic acid molecules, and uses thereof |
| 06/01/2006 | US20060115495 Protein-noble metal nanoparticles |
| 06/01/2006 | US20060115494 Recombinant BCG strains with attenuated immunosuppressive properties |
| 06/01/2006 | US20060115493 Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof |
| 06/01/2006 | US20060115491 Vaccine delivery; attaching immunogenic determinant of heterologous polypeptide biodrug to the peptidoglycan microparticle on cell wall of a Gram-positive bacterium; improve the binding by treating the cell wall with acid solution to remove protein, lipotechoic, carbohydrates |
| 06/01/2006 | US20060115490 vaccines, immunogenic compositions; diagnostics, enzymatic studies and targets for antibiotics; for treating Staphylococcus aureus infection |
| 06/01/2006 | US20060115489 Influenza immunogen and vaccine |
| 06/01/2006 | US20060115488 Identification of new CD8 epitopes from HIV-1 proteins with therapeutical and vaccinal properties against HIV infections |
| 06/01/2006 | US20060115487 Allogeneic cellular immunotherapy for invasive pulmonary aspergillosis (IPA) |
| 06/01/2006 | US20060115486 Staphylococcal PNAG/dPNAG-binding complementarity determining regions (CDR); for diagnosis and treatment of Staphylococcal and other PNAG-expressing bacterial infections |
| 06/01/2006 | US20060115485 Methods of preventing and treating RSV infections and related conditions |
| 06/01/2006 | US20060115484 Nucleic acid for modulating apoptosis |
| 06/01/2006 | US20060115483 Receptor polypeptide and polynucleotide encoding polypeptide; anticancer agents; viricides; multiple sclerosis; antiarthritic agents; cardiovascular disorders; osteoporosis |
| 06/01/2006 | US20060115482 Modifications of histone proteins as indicators of cell proliferation and differentiation |
| 06/01/2006 | US20060115481 Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy |
| 06/01/2006 | US20060115480 Disease treatment via antimicrobial peptide inhibitors |
| 06/01/2006 | US20060115479 Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof |
| 06/01/2006 | US20060115478 Compositions and methods for treating and preventing type-1 diabetes |
| 06/01/2006 | US20060115477 Neuropilin-1 inhibitors |
| 06/01/2006 | US20060115476 Antibodies anti-c5 component of the complement system and their use |
| 06/01/2006 | US20060115475 Toll like receptor 3 antagonists, methods and uses |
| 06/01/2006 | US20060115474 antihemophilic factor monoclonal antibodies comprising an immunoglobulin heavy chain and light chain amino acid sequences, with modified by enzymatic deglycosylation or by site directed mutagenesis, used for treating hemostasis disorders; anticoagulants |
| 06/01/2006 | US20060115473 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 06/01/2006 | US20060115472 Stabilizing formulations |
| 06/01/2006 | US20060115471 Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), to inhibit angiogenesis |
| 06/01/2006 | US20060115470 Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| 06/01/2006 | US20060115428 Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies |
| 06/01/2006 | US20060115424 Combination therapy of oxaliplatin and radioactively doped particles treating cancer |
| 06/01/2006 | US20060114931 IPv6/IPv4 packet conversion system |
| 06/01/2006 | DE19910102B4 Proteinkonjugate, Verfahren, Vektoren, Proteine und DNA zu deren Herstellung, deren Verwendung, sowie Arzneimittel und Impfstoffe mit einem Gehalt derselben Protein conjugates, methods, vectors, proteins, and DNA for their preparation, their use, as well as drugs and vaccines containing the same |
| 06/01/2006 | CA2630475A1 Mer diagnostic and therapeutic agents |
| 06/01/2006 | CA2589561A1 Treatment of neurodegenerative diseases by the use of laptm4a |
| 06/01/2006 | CA2589471A1 Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (pth) 1-84 |
| 06/01/2006 | CA2589163A1 Methods of studying tolerance in mhc-ii transgenic animals |
| 06/01/2006 | CA2587889A1 Antigenic epitopes of interleukin-21, related antibodies and their use in medical field |
| 06/01/2006 | CA2586093A1 Methods for cultivating lawsonia intracellularis |
| 06/01/2006 | CA2584646A1 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| 05/31/2006 | EP1662007A1 Preventive or remedy for inflammatory bowel diseases containing anti-cd81 antibody as the active ingredient |
| 05/31/2006 | EP1662003A2 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 05/31/2006 | EP1661999A1 A method of preparing epitopes chimeric gene vaccine |
| 05/31/2006 | EP1661995A1 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 05/31/2006 | EP1661915A1 Preparation of antibodies against the human chitinase-like protein GL008 |
| 05/31/2006 | EP1661911A1 Protease-resistant seb variant and vaccine containing the same |
| 05/31/2006 | EP1660664A1 Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer |
| 05/31/2006 | EP1660660A2 Polypeptides of streptococcus pyogenes |
| 05/31/2006 | EP1660653A2 Biodegradable polymer-ligand conjugates and their uses in isolation of cellular subpopulations and in cryopreservation, culture and transplantation of cells |
| 05/31/2006 | EP1660638A2 Lipoparticles comprising proteins, methods of making, and using the same |
| 05/31/2006 | EP1660636A2 Anti-cancer vaccines |
| 05/31/2006 | EP1660596A1 Microorganism coating components, coatings, and coated surfaces |
| 05/31/2006 | EP1660537A2 Endotheliase-2 ligands |
| 05/31/2006 | EP1660534A2 Humanization of antibodies |
| 05/31/2006 | EP1660533A2 Monoclonal antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
| 05/31/2006 | EP1660524A2 Identification of porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases |
| 05/31/2006 | EP1660523A2 Induction of antiviral neutralizing antibodies in humans and animals |
| 05/31/2006 | EP1660517A2 Nogo receptor antagonists |